(2024 Fan et al) - Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage
(2024 Man-Yuan Li et al) - Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells
(2024 Kaur et al) - Ivermectin: A Multifaceted drug with a potential beyond anti-parasitic therapy
(2024 Xing Hu et al) - Ivermectin as a potential therapeutic strategy for glioma
(2024 Yang Song et al) - Gene signatures to therapeutics: Assessing the potential of ivermectin against t(4;14) multiple myeloma
(2024 Goldfarb et al) - Lipid-Restricted Culture Media Reveal Unexpected Cancer Cell Sensitivities
(2024 Newell et al) - Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy
In “Ivermectin and Cancer Part 1”, I covered all the mechanisms of action that Ivermectin has shown against cancer in many in vitro and in vivo studies.
The 7 new studies published in 2024 only confirm what we already know from previous studies. Ivermectin is highly effective against many cancers.
Since my previous Ivermectin article, I‘ve had 1000s of questions sent to me. Not about mechanisms of action against Cancer. But about practical use - how to use Ivermectin to treat Stage 4 Cancers, what formulations, what doses?
The goal of this article (Part 2) is to answer all of those questions to the best of my ability.